IL17A and psoriasis vulgaris: In conclusion, the existing evidence suggests that biologic therapies including TNFi, an anti‐IL‐12/23 agent (ustekiumab) and anti‐IL‐17A agents (secukinumab and ixekizumab) had no significant impact on the risk of MACEs in adult patients with plaque psoriasis over the short term.